Jean-Pierre Routy, MD, Division of Hematology and Immunodeficiency, Royal Victoria Hospital, McGill University Health Centre; Associate Professor, Department of Medicine, Division of Experimental Medicine, McGill University, Montreal, Quebec, Canada
Dr. Routy is a recognized expert in HIV infection. His research focuses on gaining a better understanding of the immune correlate for HIV control and the role of several cytokines in T-cell reconstitution, including interleukin-2 (IL-2), interleukin-7 (IL-7) and KGF. He is also involved in conducting clinical trials on HIV immune reconstitution using IL-2 and KGF along with an HIV specific vaccine.
Selected & Recent Publications:
Mercier, F., Boulassel, M.R., Yassine-Diab, B., Tremblay, C., Bernard, N.F., Sekaly, R.P. and Routy, J.P. 2008. Persistent human immunodeficiency virus-1 antigenaemia affects the expression of interleukin-7Rα on central and effector memory CD4+ and CD8+ T cell subsets J. Clin. Exp. Immunol. April; 152(1):72-80(9).
Van Grevenynghe, J., Procopio, F.A., Hel, Z., Chomont, N., Rioul, C., Zhang, Y., Gimmig, S., Boucher, G., Wilkinson, P., Shi, Y., Yassine-Diab, B., Said, E., Trautmann, L., El Far, M., Baldera, R.S., Boulassel, M.R., Routy, J.P., Haddad, E.K. and Sekaly, R.P. 2008. Transcriptional factor FOXO3a controls the persistance of memory CD4+ T cells during HIV infection. Nat Med. Mar; 14(3):266-74.
Boulassel, M.R., Samson, J., Khammy, A., Lapointe, N., Soudeyns, H. and Routy, J.P. 2007. Predictive value of interleukin-7 levels in antiretroviral treated HIV-1 infected children. Viral Immunology 20: 649-656.
Leitch H, Trudeau M, Routy JP. 2003. Effect of Protease Inhibitor Based Highly Active Antiretroviral Therapy on Survival in HIV Associated Advanced Kaposi Sarcoma Patients Treated with Chemotherapy. HIV Clinical Trials 4:107-117.
Boulassel MR, Smith GHR, Gilmore N, Klein M, Murphy T, MacLeod JD, LeBlanc RP, Allan J, René P, Lalonde R, Routy JP. 2003. Interleukin-7 levels may predict virological response in advanced HIV-1-infected patients receiving lopinavir/ritonavir-based therapy. HIV Medicine 4:315-320.
Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, Koup RA, Mellors JW, Connick E, Conway B, Kilby M, Wang L, Whitcomb JM, Hellmann NS, Richman DD. 2002. Antiretroviral-drug resistance among patients recently infected with HIV. The New England Journal of Medicine 347: 385-394.